ONCOS-102 in checkpoint inhibitor refractory melanoma

The trial is exploring safety, immune activation, and clinical response, of ONCOS-102 and Keytruda® (pembrolizumab), an anti-PD1 checkpoint inhibitor (CPI), in patients with advanced or unresectable melanoma whose tumors have continued to grow following prior CPI therapy. The trial is being conducted at the Memorial Sloan Kettering Cancer Center in New York, USA, Fox Chase Cancer Center in Philadelphia, USA and University of Maryland Comprehensive Cancer Center in Baltimore, USA. Identifier: NCT03003676

The results from part 1 of the trial showed encouraging results:

  • One complete response (CR) and two partial responses (PR) observed for the nine patients in part 1 (33% ORR), who received only three ONCOS-102 injections
  • Innate and adaptive immune activation observed in nine out of nine patients

For more information, please see press release here.

Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma

Targovax has built on the previous immune activation and anti-tumor findings and showed that the combination of ONCOS-102 and Keytruda can generate systemic responses that reduce the size of non-injected lesions, i.e. abscopal anti-tumor effect. This work was performed in a humanized melanoma mouse model with tumors inoculated dorsally on both sides of the animals. After the tumors were established, ONCOS-102 was injected directly into the tumor on one side only, followed by systemic treatment with Keytruda. By Day 40, tumors on the non-injected side of the animals had shrunk by an average of 70%.